[go: up one dir, main page]

MX2021012871A - Generation of antibody-derived polypeptides by polypeptide chain exchange. - Google Patents

Generation of antibody-derived polypeptides by polypeptide chain exchange.

Info

Publication number
MX2021012871A
MX2021012871A MX2021012871A MX2021012871A MX2021012871A MX 2021012871 A MX2021012871 A MX 2021012871A MX 2021012871 A MX2021012871 A MX 2021012871A MX 2021012871 A MX2021012871 A MX 2021012871A MX 2021012871 A MX2021012871 A MX 2021012871A
Authority
MX
Mexico
Prior art keywords
antibody
generation
polypeptide chain
derived polypeptides
chain exchange
Prior art date
Application number
MX2021012871A
Other languages
Spanish (es)
Inventor
Guy Georges
Ulrich Brinkmann
Eike Hoffmann
Stefan Dengl
Sabine Imhof-Jung
Steffen Dickopf
Can Martin Buldun
David Zilian
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2021012871A publication Critical patent/MX2021012871A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un conjunto de polipéptidos heterodiméricos y sus usos, por ejemplo, para generar aglutinantes de antígenos multiespecíficos mediante el intercambio de cadenas polipeptídicas.The present invention relates to a set of heterodimeric polypeptides and their uses, for example, to generate multispecific antigen binders by exchanging polypeptide chains.

MX2021012871A 2019-04-25 2020-04-24 Generation of antibody-derived polypeptides by polypeptide chain exchange. MX2021012871A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19171068 2019-04-25
PCT/EP2020/061412 WO2020216878A1 (en) 2019-04-25 2020-04-24 Generation of antibody-derived polypeptides by polypeptide chain exchange

Publications (1)

Publication Number Publication Date
MX2021012871A true MX2021012871A (en) 2021-11-17

Family

ID=66334197

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012871A MX2021012871A (en) 2019-04-25 2020-04-24 Generation of antibody-derived polypeptides by polypeptide chain exchange.

Country Status (12)

Country Link
US (1) US20220033525A1 (en)
EP (1) EP3959244A1 (en)
JP (1) JP2026004426A (en)
KR (1) KR20220005031A (en)
CN (1) CN113728002B (en)
AU (1) AU2020261250A1 (en)
BR (1) BR112021020843A2 (en)
CA (1) CA3132275A1 (en)
IL (1) IL287400A (en)
MX (1) MX2021012871A (en)
TW (1) TW202106714A (en)
WO (1) WO2020216878A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5616428B2 (en) 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト Trivalent bispecific antibody
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
JP6721590B2 (en) * 2014-12-03 2020-07-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Multispecific antibody
US12312418B2 (en) 2020-12-10 2025-05-27 Invenra Inc. Orthogonal mutations for heterodimerization
EP4377347A1 (en) 2021-07-27 2024-06-05 MorphoSys AG Combinations of antigen binding molecules

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
IL132560A0 (en) 1997-05-02 2001-03-19 Genentech Inc A method for making multispecific antibodies having heteromultimeric and common components
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
KR100797667B1 (en) 1999-10-04 2008-01-23 메디카고 인코포레이티드 How to regulate transcription of foreign genes
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
WO2006106905A1 (en) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
PT1999154E (en) 2006-03-24 2013-01-24 Merck Patent Gmbh Engineered heterodimeric protein domains
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
SI2235064T1 (en) 2008-01-07 2016-04-29 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
HUE029257T2 (en) 2009-12-29 2017-02-28 Aptevo Res And Dev Llc Heterodimer binding proteins and uses thereof
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
MX359384B (en) * 2011-10-11 2018-09-25 Genentech Inc Improved assembly of bispecific antibodies.
DK2794905T3 (en) 2011-12-20 2020-07-06 Medimmune Llc MODIFIED POLYPEPTIDES FOR BISPECIFIC ANTIBODY BASIC STRUCTURES
CN114163530B (en) * 2012-04-20 2025-04-29 美勒斯公司 Methods and means for producing immunoglobulin-like molecules
JP6385357B2 (en) * 2012-11-27 2018-09-05 アジュ ユニバーシティー インダストリー−アカデミック コーオペレイション ファウンデーションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ Heterologous dimer of antibody heavy chain constant region, CH3 domain mutant pair that induces high-efficiency formation, production method and use thereof
CN105916880B (en) * 2014-01-15 2020-01-17 豪夫迈·罗氏有限公司 Fc region variants with improved protein A binding
PE20170263A1 (en) * 2014-08-04 2017-03-30 Hoffmann La Roche T-CELL ACTIVATING ANTIGEN-BINDING BI-SPECIFIC MOLECULES
JP6721590B2 (en) * 2014-12-03 2020-07-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Multispecific antibody
CN107849137B (en) * 2015-10-02 2021-11-26 豪夫迈·罗氏有限公司 Bispecific anti-CEAXCD 3T cell activating antigen binding molecules
CN106883297B (en) * 2015-12-16 2019-12-13 苏州康宁杰瑞生物科技有限公司 CH3 domain-based heterodimeric molecules, methods for their preparation and uses
EP3400246B1 (en) * 2016-01-08 2020-10-21 H. Hoffnabb-La Roche Ag Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
US20230075499A1 (en) * 2016-07-19 2023-03-09 Ibentrus, Inc. Bispecific proteins and methods for preparing same
EP3601345A1 (en) * 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
WO2018184966A1 (en) * 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Antibodies binding to steap-1
EP3688036A4 (en) * 2017-09-25 2021-06-23 Dingfu Biotarget Co., Ltd Proteinaceous heterodimer and use thereof
MX2020003497A (en) * 2017-10-20 2020-07-22 Hoffmann La Roche Method for generating multispecific antibodies from monospecific antibodies.
KR102831164B1 (en) * 2017-10-30 2025-07-07 에프. 호프만-라 로슈 아게 Method for in vivo production of multispecific antibodies from monospecific antibodies
MA50505A (en) * 2017-11-01 2020-09-09 Hoffmann La Roche 2 + 1 BISPECIFIC ANTIBODIES (CONTORSBODIES)
CN111527107B (en) * 2017-12-21 2024-10-01 豪夫迈·罗氏有限公司 Antibodies that bind to HLA-A2/WT1
AR119393A1 (en) * 2019-07-15 2021-12-15 Hoffmann La Roche ANTIBODIES THAT BIND NKG2D
CR20220256A (en) * 2019-12-18 2022-08-31 Hoffmann La Roche ANTIBODIES THAT BIND HLA-A2/MAGE-A4
IL298402A (en) * 2020-06-19 2023-01-01 Hoffmann La Roche Antibodies binding to cd3 and cd19

Also Published As

Publication number Publication date
TW202106714A (en) 2021-02-16
JP2022531128A (en) 2022-07-06
BR112021020843A2 (en) 2022-02-01
US20220033525A1 (en) 2022-02-03
IL287400A (en) 2021-12-01
CA3132275A1 (en) 2020-10-29
CN113728002A (en) 2021-11-30
CN113728002B (en) 2024-11-12
KR20220005031A (en) 2022-01-12
WO2020216878A1 (en) 2020-10-29
JP2026004426A (en) 2026-01-14
AU2020261250A1 (en) 2021-10-14
EP3959244A1 (en) 2022-03-02

Similar Documents

Publication Publication Date Title
MX2021012871A (en) Generation of antibody-derived polypeptides by polypeptide chain exchange.
MX2020011353A (en) MANUFACTURE OF CLINKER BY OXYFUELS WITHOUT RECIRCULATION OF PREHEATER EXHAUST GASES.
CO2021008696A2 (en) Cd28 antigen-binding agonist molecules that act on the tumor
PE20191150A1 (en) T-CELL RECEPTORS WITH ENHANCED PAIRING
MX2019005076A (en) COMPOUNDS AND METHODS TO MODULATE T-LYMPHOCYTE KINASE INDUCIBLE BY INTERLEUKIN 2.
CO2019003154A2 (en) Anti-PD-1 antibodies and their uses
CL2011000632A1 (en) Humanized antibody interleukin-6 receptor (il-6); variable regions and heavy or light chains thereof; nucleotide sequence that encodes it; vector; host cell; Method of production; and pharmaceutical composition that comprises it.
UY37523A (en) ANTI-OX40 ANTIBODIES AND ITS USES
MX2019011759A (en) COMPOSITION TO PRODUCE TAGATOSE AND TAGATOSE PRODUCTION PROCEDURE USING THE SAME.
ECSP18094829A (en) ANTI-CD40 ANTIBODIES AND THEIR USES
BR112021024852A2 (en) Cell culture methods and compositions for antibody production
MX2019008146A (en) Altered virus.
CL2018002639A1 (en) Immunoglobulins designed by genetic engineering with altered fcrn binding.
CR20160090A (en) MONOPALLY BIESPECFIC DIACUMS THAT CAN JOIN gpA33 AND CD3, AND THEIR USES
AR113092A1 (en) METHODS FOR MANUFACTURING AND USES OF ANTI-CD307E AND ANTI-BCMA BI-SPECIFIC CHIMERIC ANTIGEN RECEPTORS
CO2019006018A2 (en) Sepiapterin polymorphs and their salts
PE20210475A1 (en) SPECIFIC ANTIBODIES FOR IMMOGLUBIN TYPE 3 (ILT3) SIMILAR TRANSCRIPT AND ITS USES
CL2018003515A1 (en) Anti-gitr antibodies and their uses.
ECSP19055169A (en) ARYL HYDROCARBON RECEPTOR (AHR) MODULATING COMPOUNDS
ECSP19055179A (en) ARYL HYDROCARBON RECEPTOR (AHR) MODULATING COMPOUNDS
MX2017013150A (en) CHEMICAL INTERMEDIARIES DERIVED FROM BIOMASS.
MX378368B (en) ANTIGEN RECEPTORS AND THEIR USES.
ECSP20075234A (en) MONOSPECIFIC AND MULTI-SPECIFIC ANTI-TMEFF2 ANTIBODIES AND THEIR USES
BR112023003337A2 (en) BCMA CHIMERIC ANTIGEN RECEPTORS
CL2021000663A1 (en) Process for the production of synthesis gas.